Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia.
作者： K. Lindahl , R. Schvarcz , A. Bruchfeld , L. Stahle
DOI: 10.1046/J.1365-2893.2003.00475.X
关键词:
摘要: Summary. Ribavirin in combination with interferon alpha-2 or pegylated is the standard treatment for chronic hepatitis C. The current dosage recommendations ribavirin are based on body weight (bw). mainly eliminated by kidneys and we have recently shown that plasma concentrations determined primarily renal function. It therefore reasonable to hypothesize side-effects of ribavirin, i.e. anaemia, should be more closely related than dose per kg bw. A total 108 consecutive patients eligible C were studied. measured high-performance liquid chromatography (HPLC)-UV after solid-phase extraction trough samples taken 4, 8 12 weeks commenced. 213 obtained change haemoglobin level creatinine concentration was addition ribavirin. bw did not correlate drop induced non-linearly as revealed fitting a Hill equation type dose–response curve. half maximal at 4.4 μm. results from this study suggest anaemia depends This lends further support idea dosed according
sci-hub.se 参考文章(13)
Donald W. Cockcroft, Henry Gault, Prediction of Creatinine Clearance from Serum Creatinine Nephron. ,vol. 16, pp. 31- 41 ,(1976) , 10.1159/000180580
J. Frank Jen, Paul Glue, Samir Gupta, Demetris Zambas, Gerald Hajian, Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Therapeutic Drug Monitoring. ,vol. 22, pp. 555- 565 ,(2000) , 10.1097/00007691-200010000-00010
Jan-Olof Svensson, Annette Bruchfeld, Robert Schvarcz, Lars Ståhle, Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography. Therapeutic Drug Monitoring. ,vol. 22, pp. 215- 218 ,(2000) , 10.1097/00007691-200004000-00013
F.H. Ruddle, Meera Khan, Report of the committee on the genetic constitution of autosomes other than chromosomes 1,2 and 6. Cytogenetic and Genome Research. ,vol. 16, pp. 31- 53 ,(1974) , 10.1159/000130554
Alain Lafeuillade, Gilles Hittinger, Stephane Chadapaud, Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection The Lancet. ,vol. 357, pp. 280- 281 ,(2001) , 10.1016/S0140-6736(00)03618-7
R. W. Sidwell, J. H. Huffman, G. P. Khare, Lois, B. Allen, J. T. Witkowski, Roland, K. Robins, Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide Science. ,vol. 177, pp. 705- 706 ,(1972) , 10.1126/SCIENCE.177.4050.705
Michael W. Fried, Mitchell L. Shiffman, K. Rajender Reddy, Coleman Smith, George Marinos, Fernando L. Gonçales, Dieter Häussinger, Moises Diago, Giampiero Carosi, Daniel Dhumeaux, Antonio Craxi, Amy Lin, Joseph Hoffman, Jian Yu, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine. ,vol. 347, pp. 975- 982 ,(2002) , 10.1056/NEJMOA020047
O Reichard, R Schvarcz, O Weiland, Therapy of hepatitis C: Alpha interferon and ribavirin Hepatology. ,vol. 26, ,(1997) , 10.1002/HEP.510260719
Lucia De Franceschi, Giovanna Fattovich, Franco Turrini, Kodjo Ayi, Carlo Brugnara, Franco Manzato, Franco Noventa, Anna Maria Stanzial, Pietro Solero, Roberto Corrocher, Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage Hepatology. ,vol. 31, pp. 997- 1004 ,(2000) , 10.1053/HE.2000.5789
Michael P Manns, John G McHutchison, Stuart C Gordon, Vinod K Rustgi, Mitchell Shiffman, Robert Reindollar, Zachary D Goodman, Kenneth Koury, Mei-Hsiu Ling, Janice K Albrecht, None, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet. ,vol. 358, pp. 958- 965 ,(2001) , 10.1016/S0140-6736(01)06102-5